Il-1 α expression inhibitor

Abstract

To find out a new function of Myonectin and to provide a suitable use thereof.SOLUTION: The myonectin production promoter is contained in a composition for inhibiting IL-1 α expression. The composition is preferably in the form of an external preparation for skin or a food or drink.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a new use of myonectin, and specifically to an IL-1α expression inhibitor. [Background technology]

[0002] Myonectin was discovered as a type of cytokine called myokine, which is secreted from muscles (Non-Patent Document 1), but much about its physiological activity remains unknown, and various studies are being conducted. It has been found that myokines function in various ways in the skin and alter the expression of genes involved in skin condition (Patent Document 1). In particular, myonectin suppresses melanin production in melanocytes to which it has been added, leading to the proposal to use myonectin as an active ingredient in whitening compositions (Patent Document 2). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Publication No. 2020-046195 [Patent Document 2] Japanese Patent Application Publication No. 2020-015692 [Non-patent literature]

[0004] [Non-Patent Document 1] MM Seldin, et al., J. Biol. Chem., 2012 Apr 6; 287(15): 11968-11980. Summary of the Invention [Problem to be solved by the invention]

[0005] An objective of the present invention is to discover new functions of myonectin and provide suitable uses thereof. [Means for solving the problem]

[0006] As a result of intensive research, the present inventors discovered that myonectin suppresses IL-1α expression in keratinocytes, leading to the completion of the present invention.

[0007] That is, the present invention is as follows. [1] An IL-1α expression inhibitor containing myonectin. [2] The agent described in [1], which suppresses IL-1α expression in keratinocytes. [3] The agent according to [1] or [2], which is contained in a topical skin preparation. [4] The agent according to [1] or [2], which is contained in a food or beverage. [5] A composition for inhibiting IL-1α expression, containing a myonectin production promoter. [6] The composition described in [5], which is a topical skin preparation. [7] The composition described in [5], which is a food or beverage. [Effects of the Invention]

[0008] The present invention provides a new use of myonectin: the inhibition of IL-1α expression. It also provides an embodiment in which a myonectin production promoter is contained in a composition for inhibiting IL-1α expression. The agents and compositions of the present invention can be formulated as foods and beverages or topical skin preparations, allowing them to be easily and continuously incorporated into daily life. [Brief explanation of the drawings]

[0009] [Figure 1] Graph showing the expression level of IL-1α in epidermal cells cultured in the presence of myonectin. [Figure 2] A graph showing the relative expression level of myonectin gene mRNA in human skeletal muscle myoblasts treated with mango ginger extract, with the control level set at 1 (*p<0.05). [Figure 3]A graph showing the relative expression level of myonectin gene mRNA in human skeletal muscle myoblasts to which lotus flower extract was added, with the control level set at 1. [Figure 4] A graph showing the relative expression level of myonectin gene mRNA in human skeletal muscle myoblasts to which cat's claw extract was added, with the control level set at 1. [Figure 5] A graph showing the relative expression level of myonectin gene mRNA in human skeletal muscle myoblasts to which Indian date extract was added, with the control level set at 1. DETAILED DESCRIPTION OF THE INVENTION

[0010] A first aspect of the present invention is an IL-1α expression inhibitor containing myonectin. The myonectin content in the IL-1α expression inhibitor of the present invention is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 1% by mass or more, based on the total amount of the agent. Myonectin is a protein secreted from the muscles of mammals, including humans, and present in the body. However, the agent of the present invention is generally distinguished from muscles containing myonectin based on the aforementioned content.

[0011] Myonectin can be obtained by any method. For example, the protein can be biosynthesized using well-known genetic engineering techniques using the DNA of the gene (CTRP15) encoding myonectin, and then isolated and purified.

[0012] Furthermore, a component that promotes myonectin production in vivo, i.e., a myonectin production promoter, can also be used as an active ingredient for suppressing IL-1α expression. A second aspect of the present invention is a composition for suppressing IL-1α expression that contains a myonectin production promoter. The myonectin production promoter promotes myonectin production in muscle cells, and the produced myonectin suppresses IL-1α expression in keratinocytes.

[0013] A myonectin production promoter is a component that directly or indirectly enhances the expression of the myonectin gene (FAM132B) in muscle cells, including myoblasts and muscle fibers.

[0014] Myonectin production promoters include, but are not limited to, plant extracts and compounds. Preferred examples include plant extracts such as mango ginger extract, lotus flower extract, cat's claw extract, and Indian date extract. Mango ginger extract is an extract of mango ginger (Curcuma amada), a member of the Zingiberaceae family. Lotus flower extract is an extract of the flowers or flower buds of the lotus plant (Nelumbo nucifera) of the Nelumbaceae family. Cat's claw extract is an extract of Uncaria tomentosa, a plant of the Rubiaceae family. Indian date extract is an extract of Tamarindus indica, a plant of the Fabaceae family, subfamily Caesalpinioideae.

[0015] In the present invention, the above-mentioned extract is a general term that refers not only to the extract itself, but also to a fraction of the extract, a purified fraction, and a product obtained by removing the solvent from the extract or fraction, or the purified product.

[0016] The extract may be extracted from a plant body by a conventional method. For example, the whole plant (whole plant) may be used, or parts of the plant, such as the plant body, above-ground parts, rhizomes, trunks, leaves, stems, flowers, flower buds, fruits, etc. However, in the case of lotus flower extract, only the flowers or flower buds are used for the extraction procedure. The extraction solvent is preferably one or more selected from polar solvents such as water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran.

[0017] Specific extraction methods include, for example, adding 1 to 30 parts by mass of solvent to 1 part by mass of the part of the plant body or the like used for extraction or its dried product, immersing for several days at room temperature or for several hours at a temperature near the boiling point, cooling to room temperature, removing insoluble matter and / or solvent as desired, and fractionating and purifying by column chromatography or the like.

[0018] The total content of mango ginger extract, lotus flower extract, cat's claw extract, and / or Indian date extract in the composition of the present invention is preferably 0.0001 to 50% by mass, more preferably 0.001 to 30% by mass, and even more preferably 0.001 to 10% by mass, calculated as solid matter relative to the total composition. By setting the content within the above range, the desired effect can be easily obtained and the degree of freedom in formulation design can be ensured. The above content can be adjusted appropriately depending on the administration route and the type of composition to be contained, as described below.

[0019] As shown in the Examples below, keratinocytes to which myonectin has been added exhibit suppressed IL-1α expression. In particular, IL-1α expression is usually elevated in keratinocytes exposed to physical stimuli such as scratch damage, but myonectin can suppress such expression. Similar effects are also expected in keratinocytes exposed to chemical or ultraviolet stimuli. Therefore, the agent of the present invention can be suitably used to suppress IL-1α expression. Furthermore, the composition of the present invention promotes myonectin production in vivo, thereby exerting an inhibitory effect on IL-1α expression. Here, suppression of the expression level means that the expression level of the gene encoding IL-1α or the IL-1α protein is lower than when the agent or composition of the present invention is not applied.

[0020] The agents and compositions of the present invention can be suitably used for the prevention, amelioration and / or treatment of conditions and diseases caused by an increase in the amount of IL-1α, or conditions and diseases that are improved by a decrease in the amount of IL-1α.

[0021] The route of administration of the agent and composition of the present invention is not particularly limited and may be oral, transdermal, nasal, intravenous, etc., but oral administration or transdermal administration is preferred. Here, "administration" may be substituted with "ingestion."

[0022] When the agent or composition of the present invention is orally administered, it is preferably formulated as a food or drink. When the agent of the present invention is in the form of a food or beverage, the content of myonectin is preferably 0.01 to 20% by mass, more preferably 0.1 to 10% by mass, and even more preferably 1 to 5% by mass, relative to the total amount of the composition, which makes it easier to achieve the desired effect and ensures freedom in formulation design. While the preferred intake amount of the myonectin-containing foods and beverages of the present invention is not particularly limited, for adults, a daily dose of 0.001 to 1000 mg / kg (body weight) of myonectin is preferred from the perspective of fully demonstrating its effects, with 0.01 to 100 mg / kg (body weight), and even more preferred, 0.1 to 10 mg / kg (body weight). This daily amount can be taken all at once or in divided doses. In addition to single doses, it is also preferred to take the food and beverage products continuously or intermittently for several weeks to several months.

[0023] When the composition of the present invention is in the form of a food or beverage, the amount of myonectin production promoter contained therein may be adjusted appropriately depending on the production promoter. For example, in the case of a plant extract that has the effect of promoting myonectin production, it is preferable to contain an amount of 1 to 100 mg / day in solid form, to be taken in one or several divided doses. In addition to taking it once, it is also preferable to take it continuously or intermittently for several weeks to several months.

[0024] When the agent or composition of the present invention is in the form of a food or drink, ingredients that are usually used in the production of food or drink can be optionally blended therein. Examples of such optional ingredients include proteins, carbohydrates, fats, nutrients, seasonings, and flavorings. Examples of carbohydrates include monosaccharides, such as glucose and fructose; disaccharides, such as maltose, sucrose, and oligosaccharides; and polysaccharides, such as dextrin and cyclodextrin, and sugar alcohols, such as xylitol, sorbitol, and erythritol. Examples of flavorings that can be used include natural flavorings (thaumatin, stevia extract, and the like) and synthetic flavorings (saccharin, aspartame, and the like). Other additives that are commonly used in pharmaceutical compositions and are also commonly added to foods may also be used.

[0025] The form of the food or drink may be liquid, paste, solid, powder, granules, etc. Tablets, liquid food, feed, etc. are also included in the form of the food or drink.

[0026] It may also be contained in other general foods and beverages, for example, wheat flour products such as bread, macaroni, spaghetti, noodles, cake mix, fried chicken flour, and breadcrumbs; instant foods such as instant noodles, cup noodles, retort and cooked foods, canned foods, microwave foods, instant soups and stews, instant miso soup and clear soups, canned soups, and freeze-dried foods; processed agricultural products such as canned agricultural products, canned fruit, jams and marmalades, pickles, boiled beans, dried agricultural products, and cereals (processed grain products); processed marine products such as canned seafood, fish ham and sausage, fish paste products, marine delicacies, and tsukudani (simmered fish paste); processed livestock products such as canned livestock products and pastes, and livestock ham and sausage; milk and dairy products such as processed milk, milk drinks, yogurt, lactic acid bacteria drinks, cheese, ice cream, modified milk powder, cream, and other dairy products; butter, milk, basic seasonings such as soy sauce, miso, sauces, processed tomato seasonings, mirin, vinegars, etc.; complex seasonings and foods such as cooking mixes, curry bases, sauces, dressings, noodle soup bases, spices, and other complex seasonings; frozen foods such as frozen ingredients, semi-cooked frozen foods, and cooked frozen foods; sweets such as caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese sweets, rice snacks, bean snacks, and dessert sweets; beverages such as carbonated drinks, natural fruit juices, fruit juice drinks, soft drinks with fruit juice, fruit pulp drinks, fruit drinks with fruit particles, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, and alcoholic drinks; and foods other than these, the agent or composition of the present invention may be added.

[0027] The food and drink of the present invention may be in the form of ordinary foods, beverages, functional foods such as functional foods and foods for specified health uses, supplements, etc., with functional foods being particularly preferred. When the food or drink of the present invention is used to inhibit IL-1α expression, the food or drink may be labeled with information about its usefulness and functionality when it is commercialized. Such "indication" acts include all acts for informing consumers of the above-mentioned uses, and any expression that can evoke or infer a use such as "suppressing the expression of IL-1α" falls under the "indication" acts of the present invention, regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc. In addition, the "display" is made in a way that consumers can directly recognize the above-mentioned uses. Specifically, examples include the act of transferring, delivering, displaying for transfer or delivery, or importing food and beverage products or product packaging, containers, etc., on which the above-mentioned uses are written; displaying or distributing product advertisements, price lists, catalogs, pamphlets, POP, and other sales promotion materials at the point of sale, or transaction documents, or providing information containing the above-mentioned uses via electromagnetic means (such as the Internet). Note that when the food and beverage products of the present invention are approved under various systems established by the government for health claim foods, etc., and are implemented under that approval, it is preferable to label them in a manner consistent with that approval.

[0028] Preferred embodiments of transdermal administration of the agent or composition of the present invention are topical skin preparations such as cosmetics, quasi-drugs, and pharmaceuticals. The formulation of topical skin compositions is not particularly limited, and examples include lotion formulations, emulsion formulations such as lotions and creams, oil formulations, gel formulations, and pack formulations.

[0029] When the agent of the present invention is in the form of an external skin preparation, the content of myonectin is preferably 0.01 to 20% by mass, more preferably 0.1 to 10% by mass, and even more preferably 1 to 5% by mass, relative to the total amount of the composition, which makes it easier to achieve the desired effect and ensures freedom in formulation design. When the composition of the present invention is used as a topical skin preparation, the amount of myonectin production promoter contained therein can be adjusted appropriately depending on the production promoter. For example, in the case of a plant extract that has the effect of promoting myonectin production, a total amount of preferably 0.01 to 20% by mass, more preferably 0.1 to 10% by mass, and even more preferably 1 to 5% by mass of the total amount of the composition will make it easier to achieve the desired effect and ensure flexibility in formulation design.

[0030] When the agent or composition of the present invention is in the form of a topical skin preparation, it may optionally contain ingredients other than myonectin or myonectin-producing agents that are typically incorporated into topical skin compositions, as long as the effects of the present invention are not impaired. Such ingredients include, for example, oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, Ibota wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, paraffin, Hydrocarbons such as ceresin, petrolatum, and microcrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, and pentane erythritol tetra-2-ethylhexanoate. synthetic ester oils such as ritt; chain polysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane, and diphenylpolysiloxane; cyclic polysiloxanes such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexanesiloxane; oils such as silicone oils and modified polysiloxanes such as amino-modified polysiloxanes, polyether-modified polysiloxanes, alkyl-modified polysiloxanes, and fluorine-modified polysiloxanes;

[0031] Fatty acid soap (sodium laurate, sodium palmitate, etc.), lauryl sulfate Anionic surfactants such as potassium and alkyl triethanolamine ether sulfate; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, and laurylamine oxide; imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaines, amido betaines, sulfobetaines, etc.), and amphoteric surfactants such as acylmethyl taurine; sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ether, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbit fatty acid esters (POE-sorbit monolaurate, etc.), POE glycol Glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic (registered trademark) types, POE / POP alkyl ethers (POE / POP 2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hydrogenated castor oil Nonionic surfactants such as corn oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, and alkyl glucosides; polyhydric alcohols such as polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexanediol, 1,2-hexanediol, and 1,2-octanediol;

[0032] Moisturizing ingredients such as sodium pyrrolidonecarboxylate, lactic acid, sodium lactate, etc.; powders such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, anhydrous silicic acid (silica), aluminum oxide, barium sulfate, etc., which may be surface-treated; inorganic pigments such as red iron oxide, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, Prussian blue, titanium oxide, and zinc oxide, which may be surface-treated; pearlizing agents such as titanium mica, fish phosphorus foil, and bismuth oxychloride, which may be surface-treated; Red No. 202, Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, and Red No. 602, which may be laked. Organic dyes such as No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, and Red No. 204; organic powders such as polyethylene powder, polymethyl methacrylate, nylon powder, and organopolysiloxane elastomers; para-aminobenzoic acid-based UV absorbers; anthranilic acid-based UV absorbers; salicylic acid-based UV absorbers; cinnamic acid-based UV absorbers; benzophenone-based UV absorbers; sugar-based UV absorbers; UV absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane;

[0033] Lower alcohols such as ethanol and isopropanol; vitamin A or its derivatives, vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or its derivatives, vitamin B 12 , Vitamin B 15or their derivatives; vitamin E such as α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E acetate, vitamin D, vitamin H, pantothenic acid, pantethine, pyrroloquinoline quinone, etc.; antibacterial agents (preservatives) such as methylparaben, ethylparaben, butylparaben, phenoxyethanol, etc.; anti-inflammatory agents such as glycyrrhizinic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, etc.; wrinkle improvement agents such as retinol, ascorbic acid, tocopherol, or farnesyl acetate ester; various extracts (e.g., Examples include Phellodendron bark, Coptis chinensis, Lithospermum root, Peony, Swertia japonica, Birch, Sage, Loquat, Carrot, Aloe, Mallow, Iris, Grape, Job's tears, Luffa, Lily, Saffron, Cnidium rhizome, Angelica acutiloba, St. John's wort, Ononis, Garlic, Chili pepper, Citrus fruit, Angelica acutiloba, Seaweed, etc.); activators such as royal jelly, photosensitizers, cholesterol derivatives, etc.; blood circulation promoters such as nonylic acid valenylamide, capsaicin, zingerone, tannic acid, etc.; antiseborrheic agents such as sulfur and thianthol, anti-inflammatory agents such as tranexamic acid, thiotaurine, hypotaurine, etc.; water-soluble polymers such as collagen and hyaluronic acid, etc. [Example]

[0034] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples as long as it does not depart from the gist of the invention.

[0035] <Example> Examination of the effect of myonectin on IL-1α expression levels The expression level of IL-1α in keratinocytes to which myonectin had been added was measured by the following procedure. 0.5 mL of basal medium (HUMedia-KG2 medium, manufactured by Kurabo) was placed in each well of a 12-well plate, and 0.5 mL of a suspension of human keratinocytes (manufactured by Kurabo, Lot #06445) was seeded therein (6.0 × 10 4The cells were cultured at 37°C, 5% CO2, with 1.0 mL / well of medium. After culture, a scratch was made across the diameter of the well with a microspatula (specific means) to simulate physical stimulation. The medium was then replaced with 0.5 mL / well of myonectin-containing medium (100 ng / mL myonectin, HUMedia-KG2 medium, manufactured by Kurabo) and cultured at 37°C, 5% CO2 for 24 hours. After culture, the cells were washed with PBS and then collected. mRNA was extracted using a QIAcube (manufactured by QIAGEN). RT-qPCR was performed using 5 ml of Fast SYBR Green Master Mix (Applied Biosystems), Superscript VILO cDNA Synthesis kit 250T (Invitrogen), and Hs_IL1A_1_SG QuantiTect Primer Assay (QIAGEN, QT00001127, Cat. 249900) to analyze the expression level of IL-1α.

[0036] FIG. 1 shows the mRNA expression level of the IL-1α gene in keratinocytes as a relative value, with the mRNA expression level of the IL-1α gene in keratinocytes in the absence of physical stimulation set at 1. In myonectin-treated keratinocytes, the level of IL-1α gene mRNA expression was significantly lower than in untreated cells, indicating that myonectin suppresses IL-1α expression.

[0037] <Reference Example> Confirmation of the myonectin production promoting effect of various extracts Various extracts were prepared as test extracts according to the following procedure. Mango ginger extract: Dried whole mango ginger (Curcuma longa) plant of the Zingiberaceae family was added with 10 times the amount of 30% aqueous ethanol, and the extract was refluxed and freeze-dried to powder. Lotus flower extract: Dried lotus flowers and flower buds of the Nelumbo genus were added with a 10-fold volume of 30% aqueous ethanol solution, and the extract was refluxed and freeze-dried to powder. Cat's claw extract: A 10-fold volume of 30% aqueous ethanol solution was added to the dried whole plant of Cat's claw (Uncaria genus, Rubiaceae), and the extract was refluxed, and the liquid was freeze-dried to powder. Indian date extract: Dried tamarind fruit of the family Pisum sativum, subfamily Caesalpinioideae, genus Tamarindus, was added with a 10-fold volume of 30% aqueous ethanol solution, and the extract was refluxed and freeze-dried to powder.

[0038] The expression level of the myonectin gene in muscle cells to which the test extract had been added was measured using the following procedure. Human skeletal muscle myoblast cells Lonza CC-2580 (Lonza, Lot #29715) were seeded in a 24-well plate (4 × 10 4 Cells / well) were cultured in basal medium (SkGM-2 Bullet Kit (Lonza: CC-3245)) at 0.5 mL / well for 24 hours at 37°C under 5% CO2. After incubation, the basal medium was removed and washed with PBS. Differentiation medium (DMEM:F-12 (Lonza: 12-719F) + 2% Horse Serum (Gibco: 16050-130) + 1% aa (Gibco: 15240062)) was added at 1.0 mL / well and cultured at 37°C under 5% CO2 for 72 hours. After incubation, the differentiation medium was removed and 1.0 mL / well of differentiation medium containing the test extract at the designated solids concentration was added and cultured at 37°C under 5% CO2. After culturing, the cells were washed with PBS and qRT-PCR was performed using Fast SYBR Green Master Mix (Thermo Fisher Scientific), Hs_FAM132B_4_SG QuantiTect Primer Assay (QIAGEN, for measuring myonectin FAM132B gene), and Hs_TBP_1_SG QuantiTect Primer Assay (QIAGEN, endogenous control) to analyze the expression level of the myonectin gene (FAM132B).

[0039] 2 to 5 show the mRNA expression levels of the myonectin gene in muscle cells as relative values, with the mRNA expression level of the myonectin gene in solvent control muscle cells set at 1.

[0040] In muscle cells treated with each extract, the level of myonectin gene mRNA expression tended to increase compared to the control. In particular, in muscle cells treated with mango ginger extract, the level of myonectin gene mRNA expression increased significantly compared to the control. Therefore, it can be understood that these plant extracts can act as myonectin production promoters, and that their myonectin production-promoting effect can make them active ingredients in compositions for inhibiting IL-1α expression. [Industrial Applicability]

[0041] The present invention provides a new use for myonectin: suppressing IL-1α expression. It also provides an embodiment in which a myonectin production-promoting agent is used as an active ingredient in a composition for suppressing IL-1α expression. These agents and compositions can be formulated as foods, beverages, or topical skin preparations, making them highly useful industrially because they can be easily and continuously incorporated into daily life.

Claims

1. A composition for inhibiting IL-1α expression, comprising a myonectin production promoter.

2. The composition of claim 1, wherein the myonectin production promoter is selected from mango ginger extract, lotus flower extract, cat's claw extract, and Indian date extract.

3. The composition according to claim 1 or 2, which is an external preparation for skin.

4. The composition according to claim 1 or 2, which is a food or drink.

Images